In New reports coming from around the World, Researchers in France found that mild COVID-19 infections can leave people sick for months.
Two-thirds of patients who had a mild-to-moderate case of COVID-19 reported symptoms 60 days after falling ill. Whereas more than a third still felt sick or in a worse condition than when their coronavirus infection began.
Prolonged symptoms were more likely among patients aged 40 to 60 years and those who required hospitalisation, according to staff at Tours University Hospital. They followed 150 non-critical patients from March to June.
Their study, published Monday in the journal Clinical Microbiology and Infection, adds to evidence that a proportion of the 35 million people known to have been infected with the SARS-CoV-2 virus worldwide.
They will suffer lingering effects weeks to months later. Post-COVID clinics are opening in the pandemic’s wake to cater for an expanding population of so-called long-haulers — survivors left with scarred lungs, chronic heart damage, post-viral fatigue and other persistent, debilitating conditions.
Claudia Carvalho-Schneider and colleagues wrote,
“We were able to assess the evolution of the disease and demonstrate that even the mildest presentation was associated with medium-term symptoms requiring follow up Thus, the Covid-19 pandemic will involve a care burden long after its end.”
Two months after developing COVID-19 symptoms, 66% of adult patients reported suffering from at least one of 62 complaints. They mainly faced a loss of smell and taste, shortness of breath, and fatigue, the researchers found. The study sought to identify the risk of longer symptom duration in patients with non-critical COVID-19. As much of the existing international research was based on survivors admitted to intensive care units, the data is less.
How long Will Corona Last?
When will an antidote against COVID-19 finally become widely available? The answer to this question may finally be found this month. A handful of Corona vaccine candidates near the end of late stage clinical trials. At least two vaccine frontrunners — Pfizer and Moderna Inc — are set to release late-stage and Phase 2 results this month.
While experts have said vaccines were likely to reach the general public in the March-April 2021, drugmakers have been more ambitious with their calculations. Some firms like Moderna Inc are eyeing the emergency-use authorisation route to launch their shots by year end.
There are 182 vaccine candidates in pre-clinical or clinical trials across the world. Of these, 36 are in clinical trials and nine in final states of human trials.